The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
April 17th 2025
Though the rate of coronary artery lesions decreased across both cohorts of this trial of children with Kawasaki disease, there were no differences in lesion reduction between those receiving intravenous immunoglobulin (IVIG) alone and those receiving IVIG with aspirin.
Subcutaneous Immunoglobulin Shows Quality of Life Improvement in Patients With CIDP
August 25th 2021Patients with chronic inflammatory demyelinating polyneuropathy who transitioned from intravenous immune globulin to subcutaneous immune globulin showed significantly improved quality-of-life measures.
Read More
How New FDA Guidance Project Optimus May Affect Future of Oncology Clinical Trials, Drug Pipeline
August 16th 2021Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the FDA’s new guidance Project Optimus, which addresses issues relating to dose optimization in clinical trials assessing oncology drugs.
Watch
Addressing Logistical Challenges of CAR T Therapy Administration in Inpatient, Outpatient Settings
August 2nd 2021Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss how to manage the logistical challenges that arise during the administration of CAR T therapy in inpatient and outpatient settings for patients with multiple myeloma.
Watch
Study: Ibrutinib Effective Treatment for Difficult to Treat Forms of Hairy Cell Leukemia
July 27th 2021The research team noted that although HCL has a good prognosis for the majority of patients, a small population will develop variants of the disease do not respond well to existing FDA-approved therapies or cannot tolerate the adverse effects of established therapies.
Read More
FDA Approves Pembrolizumab, Lenvatinib Combination Therapy for Advanced Endometrial Carcinoma
July 22nd 2021The FDA has approved pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient
Read More
FDA Grants Breakthrough Therapy Designation to Venetoclax for Higher Risk Myelodysplastic Syndromes
July 22nd 2021Venetoclax is already approved for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in some adults with newly diagnosed acute myeloid leukemia.
Read More